{"entity":{"id":"nct05067140","kind":"trial","name":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer","aka":[],"tldr":"A phase 1/2 trial of Abiraterone acetate, Prednisone in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT05067140 by Novartis Pharmaceuticals, with 164 participants enrolled, started 2021-09-02 and due to reach its primary completion in 2027-05-25. Interventions recorded: ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone), Androgen Deprivation Therapy (ADT). Conditions listed: Prostate Cancer Metastatic. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05067140","url":"https://clinicaltrials.gov/study/NCT05067140"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["abiraterone","prednisone"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05067140","phase":"1/2","setting":"A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer","sponsor":"Novartis Pharmaceuticals","enrolled":164,"outcomes":[]},"route":"/trials/nct05067140/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}